184 related articles for article (PubMed ID: 10528784)
1. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics.
Turnidge J
Int J Antimicrob Agents; 1999 Aug; 12 Suppl 2():S23-34. PubMed ID: 10528784
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.
Bulitta JB; Okusanya OO; Forrest A; Bhavnani SM; Clark K; Still JG; Fernandes P; Ambrose PG
Antimicrob Agents Chemother; 2013 Jan; 57(1):498-507. PubMed ID: 23147726
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers.
Macgowan AP; Greig MA; Andrews JM; Reeves DS; Wise R
J Chemother; 1989 Jul; 1(4 Suppl):593-6. PubMed ID: 16312548
[No Abstract] [Full Text] [Related]
4. Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection.
Okusanya OO; Tsuji BT; Bülitta JB; Forrest A; Bulik CC; Bhavnani SM; Fernandes P; Ambrose PG
Diagn Microbiol Infect Dis; 2011 May; 70(1):101-11. PubMed ID: 21513848
[TBL] [Abstract][Full Text] [Related]
5. [Comparative diffusion of fusidic acid, oxacillin, and pristinamycin in dermal interstitial fluid after repeated oral administration].
Vaillant L; Le Guellec C; Jehl F; Barruet R; Sorensen H; Roiron R; Autret-Leca E; Lorette G
Ann Dermatol Venereol; 2000 Jan; 127(1):33-9. PubMed ID: 10717560
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of fusidic acid after a single dose of a new paediatric suspension.
Bourget P; Duhamel JF; Sørensen H; Roiron R
J Clin Pharm Ther; 1993 Jun; 18(3):171-7. PubMed ID: 8345001
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis.
Brown NM; Reeves DS; McMullin CM
J Antimicrob Chemother; 1997 Jun; 39(6):803-9. PubMed ID: 9222051
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects.
Still JG; Clark K; Degenhardt TP; Scott D; Fernandes P; Gutierrez MJ
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S504-12. PubMed ID: 21546627
[TBL] [Abstract][Full Text] [Related]
9. Fusidic acid in dermatology: an updated review.
Schöfer H; Simonsen L
Eur J Dermatol; 2010; 20(1):6-15. PubMed ID: 20007058
[TBL] [Abstract][Full Text] [Related]
10. Fusidic acid viscous eyedrops--an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists.
Doughty MJ; Dutton GN
Ophthalmic Physiol Opt; 2006 Jul; 26(4):343-61. PubMed ID: 16792734
[TBL] [Abstract][Full Text] [Related]
11. Fusidic acid resistance in Staphylococcus aureus isolates.
Brown EM; Thomas P
Lancet; 2002 Mar; 359(9308):803. PubMed ID: 11888633
[No Abstract] [Full Text] [Related]
12. A bioavailability comparison in rabbits after a single topical ocular application of prednisolone acetate formulated as a high-viscosity gel and as an aqueous suspension.
Johansen S; Rask-Pedersen E; Prause JU
Acta Ophthalmol Scand; 1996 Jun; 74(3):253-8. PubMed ID: 8828722
[TBL] [Abstract][Full Text] [Related]
13. Corneal and intraocular penetration of topical and subconjunctival fusidic acid.
Taylor PB; Burd EM; Tabbara KF
Br J Ophthalmol; 1987 Aug; 71(8):598-601. PubMed ID: 3651375
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid.
Marsot A; Ménard A; Dupouey J; Muziotti C; Guilhaumou R; Blin O
Br J Clin Pharmacol; 2017 May; 83(5):1039-1047. PubMed ID: 27813241
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic investigation of fusidic acid 1% viscous eye drops in healthy volunteers.
Thorn P; Johansen S
Eur J Ophthalmol; 1997; 7(1):9-12. PubMed ID: 9101188
[TBL] [Abstract][Full Text] [Related]
16. Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use.
Sule O; Brown NM; Willocks LJ; Day J; Shankar S; Palmer CR; Burrows NP
Int J Antimicrob Agents; 2007 Jul; 30(1):78-82. PubMed ID: 17475448
[TBL] [Abstract][Full Text] [Related]
17. An ocular bioavailability comparison in rabbits of prednisolone acetate after repeated topical applications formulated as a high-viscosity gel and as an aqueous suspension.
Johansen S; Rask-Pedersen E; Prause JU
Acta Ophthalmol Scand; 1996 Jun; 74(3):259-64. PubMed ID: 8828723
[TBL] [Abstract][Full Text] [Related]
18. In vitro percutaneous absorption of fusidic acid and betamethasone 17-valerate across canine skin.
Degim IT; Hadgraft J; Houghton E; Teale P
J Small Anim Pract; 1999 Nov; 40(11):515-8. PubMed ID: 10649594
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of fusidic acid in therapy of experimental Staphylococcus aureus meningitis.
Østergaard C; Yieng-Kow RV; Knudsen JD; Frimodt-Møller N; Espersen F
J Antimicrob Chemother; 2003 May; 51(5):1301-5. PubMed ID: 12697637
[TBL] [Abstract][Full Text] [Related]
20. Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in
Siala W; Rodriguez-Villalobos H; Fernandes P; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
